Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes
US-12173314-B2 · Dec 24, 2024 · US
Vesicular stomatitis viruses
US9428736B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9428736-B2 |
| Application number | US-201113820453-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 1, 2011 |
| Priority date | Sep 2, 2010 |
| Publication date | Aug 30, 2016 |
| Grant date | Aug 30, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This document provides methods and materials related to vesicular stomatitis viruses. For example, vesicular stomatitis viruses, nucleic acid molecules encoding VSV polypeptides, methods for making vesicular stomatitis viruses, and methods for using vesicular stomatitis viruses to treat cancer are provided.
First claim
Opening claim text (preview).
What is claimed is: 1. A vesicular stomatitis virus comprising an RNA molecule, wherein said RNA molecule comprises, in a 3′ to 5′ direction, a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV N polypeptide, a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV P polypeptide, a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV M polypeptide, a nucleic acid sequence that is a template for a positive sense transcript encoding an interferon (IFN) polypeptide, a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV G polypeptide, a nucleic acid sequence that is a template for a positive sense transcript encoding a Sodium Iodide Symporter (NIS) polypeptide, and a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV L polypeptide, wherein said positive sense transcript encoding said IFN polypeptide comprises CUAACAG followed by a sequence encoding said IFN polypeptide followed by UAUGAAAAAAA (RNA of SEQ ID NO:1), and wherein said positive sense transcript encoding said NIS polypeptide comprises CUAACAG followed by a sequence encoding said NIS polypeptide followed by UAUGAAAAAAA (RNA of SEQ ID NO:1). 2. The virus of claim 1 , wherein said IFN polypeptide is a human IFN beta polypeptide. 3. The virus of claim 1 , wherein said NIS polypeptide is a human NIS polypeptide. 4. The virus of claim 1 , wherein said virus expresses said IFN polypeptide when said virus infects a mammalian cell. 5. The virus of claim 1 , wherein said virus expresses said NIS polypeptide when said virus infects a mammalian cell. 6. A composition comprising a vesicular stomatitis virus comprising RNA molecule, wherein said RNA molecule comprises, in a 3′ to 5′ direction, a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV N polypeptide, a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV P polypeptide, a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV M polypeptide, a nucleic acid sequence that is a template for a positive sense transcript encoding an IFN polypeptide, a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV G polypeptide, a nucleic acid sequence that is a template for a positive sense transcript encoding a NIS polypeptide, and a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV L polypeptide, wherein said positive sense transcript encoding said IFN polypeptide comprises CUAACAG followed by a sequence encoding said IFN polypeptide followed by UAUGAAAAAAA (RNA of SEQ ID NO:1), and wherein said positive sense transcript encoding said NIS polypeptide comprises CUAACAG followed by a sequence encoding said NIS polypeptide followed by UAUGAAAAAAA (RNA of SEQ ID NO:1). 7. The composition of claim 6 , wherein said IFN polypeptide is a human IFN beta polypeptide. 8. The composition of claim 6 , wherein said NIS polypeptide is a human NIS polypeptide. 9. The composition of claim 6 , wherein said virus expresses said IFN polypeptide when said virus infects a mammalian cell. 10. The composition of claim 6 , wherein said virus expresses said NIS polypeptide when said virus infects a mammalian cell. 11. A nucleic acid molecule comprising a nucleic acid strand comprising, in a 3′ to 5′ direction, a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV N polypeptide, a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV P polypeptide, a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV M polypeptide, a nucleic acid sequence that is a template for a positive sense transcript encoding an IFN polypeptide, a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV G polypeptide, a nucleic acid sequence that is a template for a positive sense transcript encoding a NIS polypeptide, and a nucleic acid sequence that is a template for a positive sense transcript encoding a VSV L polypeptide, wherein said positive sense transcript encoding said IFN polypeptide comprises CUAACAG followed by a sequence encoding said IFN polypeptide followed by UAUGAAAAAAA (RNA of SEQ ID NO:1), and wherein said positive sense transcript encoding said NIS polypeptide comprises CUAACAG followed by a sequence encoding said NIS polypeptide followed by UAUGAAAAAAA (RNA of SEQ ID NO:1). 12. The nucleic acid molecule of claim 11 , wherein said IFN polypeptide is a human IFN beta polypeptide. 13. The nucleic acid molecule of claim 11 , wherein said NIS polypeptide is a human NIS polypeptide.
Assignees
Inventors
Classifications
viral genome or elements thereof as genetic vector · CPC title
Viral vectors · CPC title
- A61K48/0075Primary
characterised by an aspect of the delivery route, e.g. oral, subcutaneous · CPC title
Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)} · CPC title
Antineoplastic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9428736B2 cover?
- This document provides methods and materials related to vesicular stomatitis viruses. For example, vesicular stomatitis viruses, nucleic acid molecules encoding VSV polypeptides, methods for making vesicular stomatitis viruses, and methods for using vesicular stomatitis viruses to treat cancer are provided.
- Who is the assignee on this patent?
- Russell Stephen James, Naik Shruthi, Mayo Foundation
- What technology area does this patent fall under?
- Primary CPC classification A61K48/0075. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 30 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).